Full Paper
3
2
22.3 (d, J(C,P)=1.2 Hz; NCHCH3), 48.3 (d, J(C,P)=4.8 Hz; NCHCH3),
120.9 (q, 1J(C,F)=318.8 Hz; CF3), 128.3 (s; CHAr), 128.6 (s; CHAr),
128.8 (s; CHAr), 130.3 (s; CHAr), 130.9 (s; CHAr), 132.3 (d, 3J(C,P)=
24.1 Hz; Cipso), 132.9 (d, 3J(C,P)=28.7 Hz; Cipso), 133.2 (d, 1J(C,P)=
102.7 Hz; PCH), 134.2 (s; CHAr), 157.2 (d, 2J(C,P)=33.4 Hz; NCꢀC),
183.2 ppm (d, 2J(C,P)=7.4 Hz; N=C); 19F NMR (282.4 MHz, 298 K,
CDCl3): d=ꢀ77.4 ppm; 29Si NMR (59.0 MHz, 298 K, CDCl3): d=
28.1 ppm; 31P{1H} NMR (121.5 MHz, 298 K, CDCl3): d=66.1 ppm;
HRMS (DCI, CH4): m/z calcd for C27H39N3P: 436.2882 [M]+; found:
436.2881.
ꢀ408C. 1H NMR (400.1 MHz, 233 K, [D8]THF): d=1.32 (m, 6H;
NCHCH3), 1.41 (d, 3J(H,H)=6.8 Hz, 12H; NCHCH3), 1.42 (m, 1H;
2
3
CH2cycle), 1.48 (m, 6H; NCHCH3), 1.89 (ddd, J(H,H)=4.0 Hz, J(H,H)=
6.4 Hz, 3J(H,P)=13.0 Hz, 1H; CH2cycle), 2.10 (ddd, 3J(H,H)=5.6 Hz,
3
3J(H,H)=6.4 Hz, J(H,P)=7.6 Hz, 1H; CHcycle), 3.66 (m, 1H; NCHCH3),
3.69 (s, 3H; OCH3), 3.99 (m, 1H; NCHCH3), 4.09 (m, 2H; NCHCH3),
7.00–7.01 (m, 3H; CHAr), 7.01–7.02 (m, 2H; CHAr), 7.20–7.21 (m, 1H;
CHAr), 7.26–7.28 (m, 2H; CHAr), 7.39–7.41 ppm (m, 2H; CHAr); 13C{1H}
NMR (100.1 MHz, 233 K, [D8]THF): d=21.3 (s; NCHCH3), 22.3 (d,
3
2J(C,P)=2.8 Hz; CH2cycle), 22.5 (s; NCHCH3), 25.1 (d, J(C,P)=3.2 Hz;
2
1
NCHCH3), 26.6 (d, J(C,P)=7.2 Hz; CHcycle), 37.3 (d, J(C,P)=96.7 Hz;
PC), 47.1 (s; NCHCH3), 47.6 (s; NCHCH3), 47.9 (s; NCHCH3), 51.7 (s;
OCH3), 109.6 (d, 2J(C,P)=36.6 Hz; NC=C), 125.8 (s; CHAr), 126.6 (s;
CHAr), 128.3 (s; CHAr), 128.9 (s; CHAr), 138.3 (d, 3J(C,P)=12.8 Hz;
Cipso), 139.9 (d, J(C,P)=24.6 Hz; Cipso), 151.9 (d, J(C,P)=8.1 Hz; Nꢀ
C), 172.4 ppm (d, 3J(C,P)=5.3 Hz; C=O); 31P{1H} NMR (161.9 MHz,
233 K, [D8]THF): d=75.7 ppm.
Azavinylidene phosphorane 6b
Phosphonium salt 5’b (100 mg, 0.17 mmol) and potassium hexam-
ethyldisilazane (35 mg, 0.17 mmol) were dissolved in [D8]THF
(0.6 mL) at ꢀ808C. Cyclic azavinylidene phosphorane 6b was ob-
tained and characterized by multinuclear NMR spectroscopy at
ꢀ808C without further purification. 1H NMR (300.1 MHz, 193 K,
[D8]THF): d=1.42 (d, 3J(H,H)=7.2 Hz, 12H; NCHCH3), 1.44 (d,
3J(H,H)=7.8 Hz, 12H; NCHCH3), 4.50 (m, 4H; NCHCH3), 7.30 (m, 3H;
CHAr), 7.45 (m, 2H; CHAr), 7.49 (m, 2H; CHAr), 7.61 ppm (m, 3H;
CHAr); 13C{1H} NMR (75.1 MHz, 193 K, [D8]THF): d=23.2 (s; NCHCH3),
42.4 (s; NCHCH3), 123.9 (s; CHAr), 125.0 (s; CHAr), 125.8 (s; CHAr),
126.8 (s; CHAr), 127.8 (s; CHAr), 128.7 (s; CHAr), 135.5 (d, 3J(C,P)=
40.4 Hz; Cipso), 142.1 (d, 3J(C,P)=56.7 Hz; Cipso), 156.6 (d, 2J(C,P)=
9.2 Hz; NC=C), 175.9 (d, 2J(C,P)=42.1 Hz; NꢀC), 234.4 ppm (d,
1J(C,P)=93.6 Hz; PC); 31P{1H} NMR (121.5 MHz, 193 K, [D8]THF): d=
95.8 ppm.
3
2
Spirophosphonium salt 9
Phosphonium salt 5’b (182 mg, 0.31 mmol) and potassium hexam-
ethyldisilazane (61.7 mg, 0.31 mmol) were dissolved in THF
(3.0 mL) at ꢀ808C. After 30 min, methylacrylate (56 mL, 0.62 mmol)
was added and the solution was kept at ꢀ608C for 48 h. One
equivalent of methyltriflate (35 mL, 0.31 mmol) was added at
ꢀ608C, then the solution was warmed up to room temperature.
All volatiles were removed under vacuum, and the crude was
washed with diethyl ether (3ꢅ2 mL). Spirophosphonium salt 9 was
obtained as a white powder (95.6 mg, 45% yield). M.p. 142–1448C;
3
1H NMR (300.1 MHz, 298 K, CDCl3): d=1.45 (d, J(H,H)=6.9 Hz, 6H;
Azaphosphetane 7
3
3
NCHCH3), 1.48 (d, J(H,H)=6.9 Hz, 6H; NCHCH3), 1.49 (d, J(H,H)=
6.6 Hz, 6H; NCHCH3), 1.50 (d, 3J(H,H)=6.6 Hz, 6H; NCHCH3), 1.52
(m, 1H; CH2cycle), 2.11 (ddd, 2J(H,H)=4.5 Hz, 3J(H,H)=6.6 Hz,
3J(H,P)=16.5 Hz, 1H; CH2cycle), 2.49 (ddd, 3J(H,H)=6.6 Hz, 3J(H,H)=
Phosphonium salt 5’b (60 mg, 0.10 mmol) and potassium hexame-
thyldisilazane (20 mg, 0.10 mmol) were dissolved in [D8]THF
(0.6 mL) at ꢀ808C. The solution was slowly warmed up to room
temperature. Azaphosphetane 7 was obtained quantitatively (indi-
cated by 31P NMR spectroscopy) and analyzed without further pu-
rification (43.5 mg). 1H NMR (300.1 MHz, 298 K, C6D6): d=0.88 (d,
3J(H,H)=6.3 Hz, 3H; NCHCH3), 1.14 (d, 3J(H,H)=6.8 Hz, 6H;
3
3
9.0 Hz, J(H,P)=16.5 Hz, 1H; CHcycle), 2.75 (d, J(H,P)=10.5 Hz, 3H;
NCH3), 3.79 (s, 3H; OCH3), 3.95 (sept d, 3J(H,H)=6.6 Hz, 2J(H,P)=
13.2 Hz, 2H; NCHCH3), 4.03 (sept d, 3J(H,H)=7.2 Hz, 2J(H,P)=
14.4 Hz, 2H; NCHCH3), 6.80–6.89 (m, 2H; CHAr), 6.94–7.05 (m, 2H;
CHAr), 7.19–7.21 (m, 3H; CHAr), 7.21–7.22 ppm (m, 3H; CHAr); 13C{1H}
3
3
NCHCH3), 1.26 (d, J(H,H)=6.3 Hz, 6H; NCHCH3), 1.28 (d, J(H,H)=
6.6 Hz, 3H; NCHCH3), 1.33 (s, 3H; NCCH3), 1.44 (s, 3H; NCCH3), 3.18
(sept, 3J(H,H)=6.8 Hz, 3J(P,H)=7.8 Hz, 1H; NCHCH3), 3.37 (d,
2J(H,P)=12.0 Hz, 1H; PCH), 3.63 (m, 2H; NCHCH3), 6.81–6.87 (m,
2H; CHAr), 7.04–7.08 (m, 3H; CHAr), 7.09–7.11 (m, 2H; CHAr), 7.18–
7.20 (m, 2H; CHAr), 7.91–7.94 ppm (m, 1H; CHAr); 13C{1H} NMR
(75.1 MHz, 298 K, C6D6): d=21.3 (d, 3J(C,P)=5.6 Hz; NCCH3), 22.4
(brs; NCHCH3), 22.9 (brs, NCHCH3), 23.4 (d, 3J(C,P)=6.6 Hz;
NCHCH3), 24.1 (d, 3J(C,P)=6.1 Hz; NCHCH3), 32.4 (d, 3J(C,P)=
3
NMR (75.1 MHz, 298 K, CDCl3): d=22.1 (d, J(C,P)=0.8 Hz; NCHCH3),
23.7 (s; NCHCH3), 23.8 (s; NCHCH3), 23.9 (s; CH2cycle), 25.2 (d,
3J(C,P)=2.2 Hz; NCHCH3), 29.4 (d, 3J(C,P)=5.7 Hz; CHcycle), 30.6 (d,
1J(C,P)=134.4 Hz; PC), 34.9 (d, 2J(C,P)=1.0 Hz; NCH3), 49.9 (d,
2
2J(C,P)=4.8 Hz; NCHCH3), 50.0 (d, J(C,P)=4.9 Hz; NCHCH3), 53.1 (s;
OCH3), 116.5 (d, 2J(C,P)=18.6 Hz; NC=C), 126.4 (s; CHAr), 126.6 (s;
3
CHAr), 126.7 (s; CHAr), 129.2 (s; CHAr), 129.6 (d, J(C,P)=8.1 Hz; Cipso),
130.2 (d, 3J(C,P)=9.5 Hz; Cipso), 131.2 (s; CHAr), 170.3 (d, 2J(C,P)=
5.6 Hz; NꢀC), 174.8 ppm (s; C=O); 31P{1H} NMR (121.5 MHz, 298 K,
CDCl3): d=72.7 ppm; HRMS (DCI, CH4): m/z calcd for C32H47N3O2P:
536.3406 [M]+; found: 536.3412.
2
2
10.3 Hz; NCCH3), 44.7 (d, J(C,P)=3.8 Hz; NCHCH3), 47.4 (d, J(C,P)=
4.9 Hz; NCHCH3), 61.9 (d, 1J(C,P)=54.7 Hz; PCH), 66.7 (d, 2J(C,P)=
2
6.7 Hz; NC(CH3)2), 110.8 (d, J(C,P)=17.3 Hz; N-C=C), 122.5 (s; CHAr),
127.4 (s; CHAr), 127.6 (s; CHAr), 127.9 (s; CHAr), 128.2 (s; CHAr), 129.6
3
3
(s; CHAr), 141.3 (d, J(C,P)=15.6 Hz; Cipso), 142.4 (d, J(C,P)=30.1 Hz;
Cipso), 162.7 ppm (d, 2J(C,P)=17.2 Hz; NꢀC); 31P{1H} NMR
(121.5 MHz, 298 K, C6D6): d=66.6 ppm.
Rhodium–cyclooctadiene complex 10
Phosphonium salt 5’b (100 mg, 0.17 mmol) and potassium hexam-
ethyldisilazane (35 mg, 0.18 mmol) were dissolved in THF (2 mL) at
ꢀ808C. After 30 min,
a solution of [{RhCl(cod)}2] (42 mg,
Spirophosphazene 8
0.085 mmol) in THF (1 mL) was added and stirred for 15 h at
ꢀ808C. Then the solution was warmed up to room temperature
and the volatile material was removed under vacuum. The crude
was washed with diethyl ether (2ꢅ2 mL) and complex 10 was ex-
tracted with dichloromethane. Red crystals of 10 were grown from
a dichloromethane/diethyl ether solution at ꢀ308C (82 mg, 71%
yield). M.p. 159–1618C; 1H NMR (300.1 MHz, 298 K, [D8]THF): d=
1.46 (d, 3J(H,H)=4.2 Hz, 12H; NCHCH3), 1.50 (d, 3J(H,H)=6.9 Hz,
Phosphonium salt 5’b (60 mg, 0.10 mmol) and potassium hexame-
thyldisilazane (20 mg, 0.10 mmol) were dissolved in [D8]THF
(0.7 mL) at ꢀ808C. After 30 min, methylacrylate (18.9 mL,
0.21 mmol) was added and the solution was kept at ꢀ608C for
48 h. Spiro derivative 8 was obtained quantitatively as indicated by
31P NMR spectroscopy. This product is not stable at room tempera-
ture and was analyzed by multinuclear NMR spectroscopy at
Chem. Eur. J. 2014, 20, 12528 – 12536
12534
ꢃ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim